1. Home
  2. NHI vs MIRM Comparison

NHI vs MIRM Comparison

Compare NHI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NHI
  • MIRM
  • Stock Information
  • Founded
  • NHI 1991
  • MIRM 2018
  • Country
  • NHI United States
  • MIRM United States
  • Employees
  • NHI N/A
  • MIRM N/A
  • Industry
  • NHI Real Estate Investment Trusts
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • NHI Real Estate
  • MIRM Health Care
  • Exchange
  • NHI Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • NHI 3.7B
  • MIRM 3.8B
  • IPO Year
  • NHI 1991
  • MIRM 2019
  • Fundamental
  • Price
  • NHI $75.69
  • MIRM $67.97
  • Analyst Decision
  • NHI Buy
  • MIRM Strong Buy
  • Analyst Count
  • NHI 4
  • MIRM 12
  • Target Price
  • NHI $82.75
  • MIRM $81.58
  • AVG Volume (30 Days)
  • NHI 204.1K
  • MIRM 492.9K
  • Earning Date
  • NHI 11-06-2025
  • MIRM 11-04-2025
  • Dividend Yield
  • NHI 4.89%
  • MIRM N/A
  • EPS Growth
  • NHI 6.78
  • MIRM N/A
  • EPS
  • NHI 3.14
  • MIRM N/A
  • Revenue
  • NHI $350,596,000.00
  • MIRM $471,794,000.00
  • Revenue This Year
  • NHI $4.68
  • MIRM $53.14
  • Revenue Next Year
  • NHI $10.60
  • MIRM $19.83
  • P/E Ratio
  • NHI $24.00
  • MIRM N/A
  • Revenue Growth
  • NHI 7.21
  • MIRM 53.66
  • 52 Week Low
  • NHI $65.13
  • MIRM $36.88
  • 52 Week High
  • NHI $82.32
  • MIRM $78.55
  • Technical
  • Relative Strength Index (RSI)
  • NHI 53.25
  • MIRM 40.15
  • Support Level
  • NHI $72.94
  • MIRM $68.71
  • Resistance Level
  • NHI $76.46
  • MIRM $74.00
  • Average True Range (ATR)
  • NHI 1.71
  • MIRM 2.95
  • MACD
  • NHI 0.20
  • MIRM -0.28
  • Stochastic Oscillator
  • NHI 89.58
  • MIRM 22.68

About NHI National Health Investors Inc.

National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: